Citadel Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Citadel Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.33M	Buy	139,318 +7,618	+6%	+$59.2K	﹤0.01%	7015
2025 Q4	$1.03M	Buy	131,700 +16,000	+14%	+$116K	﹤0.01%	7337
2025 Q3	$878K	Sell	115,700 -600	-0.5%	-$5K	﹤0.01%	7820
2025 Q2	$1.04M	Buy	116,300 +21,700	+23%	+$202K	﹤0.01%	6990
2025 Q1	$710K	Sell	94,600 -60,400	-39%	-$487K	﹤0.01%	7711
2024 Q4	$1.17M	Buy	155,000 +13,400	+9%	+$102K	﹤0.01%	6706
2024 Q3	$1.08M	Sell	141,600 -70,500	-33%	-$536K	﹤0.01%	6737
2024 Q2	$1.31M	Sell	212,100 -13,800	-6%	-$76.2K	﹤0.01%	6088
2024 Q1	$1.15M	Buy	225,900 +19,300	+9%	+$109K	﹤0.01%	6648
2023 Q4	$1.24M	Buy	206,600 +123,800	+150%	+$717K	﹤0.01%	6271
2023 Q3	$586K	Buy	82,800 +20,500	+33%	+$147K	﹤0.01%	7711
2023 Q2	$439K	Sell	62,300 -30,100	-33%	-$242K	﹤0.01%	8223
2023 Q1	$771K	Sell	92,400 -126,600	-58%	-$1.22M	﹤0.01%	7367
2022 Q4	$2.51M	Sell	219,000 -20,800	-9%	-$259K	﹤0.01%	5060
2022 Q3	$3.02M	Sell	239,800 -58,500	-20%	-$753K	﹤0.01%	4796
2022 Q2	$3.16M	Sell	298,300 -69,300	-19%	-$715K	﹤0.01%	4668
2022 Q1	$5.98M	Sell	367,600 -54,600	-13%	-$876K	﹤0.01%	3837
2021 Q4	$5.85M	Sell	422,200 -423,300	-50%	-$5.6M	﹤0.01%	4029
2021 Q3	$12.2M	Buy	845,500 +273,500	+48%	+$4.31M	﹤0.01%	2736
2021 Q2	$9.04M	Sell	572,000 -51,000	-8%	-$693K	﹤0.01%	3233
2021 Q1	$6.34M	Buy	623,000 +217,400	+54%	+$2.24M	﹤0.01%	3776
2020 Q4	$3.02M	Buy	405,600 +139,500	+52%	+$719K	﹤0.01%	4574
2020 Q3	$914K	Buy	266,100 +45,600	+21%	+$195K	﹤0.01%	6201
2020 Q2	$1.05M	Buy	220,500 +137,900	+167%	+$551K	﹤0.01%	5743
2020 Q1	$165K	Buy	82,600 +58,700	+246%	+$162K	﹤0.01%	8198
2019 Q4	$82K	Buy	+23,900	New	+$60.1K	﹤0.01%	8619
2019 Q3	–	Sell	-72,600	Closed	-$275K	–	9151
2019 Q2	$275K	Buy	72,600 +61,500	+554%	+$370K	﹤0.01%	7714
2019 Q1	$90K	Buy	+11,100	New	+$95K	﹤0.01%	8593
2018 Q1	–	Sell	-12,100	Closed	-$59K	–	8264
2017 Q4	$59K	Sell	12,100 -26,100	-68%	-$126K	﹤0.01%	7583
2017 Q3	$200K	Buy	+38,200	New	+$196K	﹤0.01%	6694
2017 Q1	–	Sell	-13,000	Closed	-$82K	–	7428
2016 Q4	$82K	Sell	13,000 -11,400	-47%	-$59.3K	﹤0.01%	6744
2016 Q3	$108K	Buy	+24,400	New	+$97.5K	﹤0.01%	6624
2016 Q1	–	Sell	-13,400	Closed	-$138K	–	6783
2015 Q4	$138K	Sell	13,400 -6,800	-34%	-$67.6K	﹤0.01%	6314
2015 Q3	$230K	Buy	20,200 +13,400	+197%	+$179K	﹤0.01%	5954
2015 Q2	$102K	Buy	6,800 +2,300	+51%	+$26.1K	﹤0.01%	7051
2015 Q1	$41K	Sell	4,500 -10,100	-69%	-$105K	﹤0.01%	7500
2014 Q4	$178K	Sell	14,600 -3,400	-19%	-$37.6K	﹤0.01%	6105
2014 Q3	$176K	Sell	18,000 -8,700	-33%	-$107K	﹤0.01%	5852
2014 Q2	$340K	Sell	26,700 -11,100	-29%	-$108K	﹤0.01%	4881
2014 Q1	$400K	Buy	37,800 +20,900	+124%	+$223K	﹤0.01%	4665
2013 Q4	$128K	Buy	16,900 +9,200	+119%	+$58.3K	﹤0.01%	5410
2013 Q3	$56K	Buy	7,700 +6,900	+863%	+$35K	﹤0.01%	5723
2013 Q2	$1K	Buy	+800	New	+$1.38K	﹤0.01%	6434

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Citadel Advisors's BCRX Position: Q1 2026 in Review

Citadel Advisors reduced its BioCryst Pharmaceuticals (BCRX) stake by 22% in Q1 2026, selling an estimated $2.18M and leaving 1,018,743 shares worth $9.7M. The position accounts for ﹤0.01% of the portfolio, ranked #3305.

Citadel Advisors first reported a position in BCRX in Q2 2013 and has held it in 45 quarters since. The position peaked at $48.4M in Q4 2020. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

Citadel Advisors held 1,018,743 shares of BioCryst Pharmaceuticals worth $9.7M as of Q1 2026.
Citadel Advisors sold 280,159 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $2.18M.
BioCryst Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3305 holding.
Citadel Advisors first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 45 quarters since.
Citadel Advisors's BioCryst Pharmaceuticals position peaked at $48.4M in Q4 2020.
301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.